Determine the necessary mass, volume, or concentration for preparing a solution.
ODN 2088 - ≥90% , CAS No.1146541-45-8
AVAILABLE TO ORDER
GRADE & PURITY ≥90%
Storage
Store at -20°C,Desiccated
Shipped In
Ice chest + Ice pads
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥90% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C,Desiccated Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
ODN 2088 is a potent TLR3 , TLR7 and TLR9 inhibitor. ODN 2088 shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6 .
In Vitro
ODN 2088 (0.01, 0.1, 1, 10 μM; 48 h) shows no cytotoxic for for human PBMCs. ODN 2088 (0.01, 0.1, 1, 10 μM; 24 h) inhibits the release of IFN-α in CpG-ODN 2216 (3 μM) and TLR7-ligand RNA-ORN 22075 (5 μM) stimulated human PBMCs. ODN 2088 (0.01, 0.1, 1, 10 μM; 48 h) hardly inhibits the IL-6 release stimulated with CpG-ODN 2006 (100 nM) but inhibits the IL-6 release stimulated with imiquimod (5 μg/ml) in human PBMCs. ODN 2088 (0.1, 1, 10 μM; 24 h) hardly inhibits IL-6 release by B-cells stimulated with CpG-DNA 2006 (100 nM) but inhibits the IL-6 release by imiquimod (5 μg/ml) stimulated human B-cells. ODN 2088 (1, 10 μM; 48 h) increases the expression of CD86 and HLA-DR in the absence of CpG-ODN 2006 or imiquimod in CD20 + B-cells. ODN 2088 presumably impairs TLR9-induced signaling induces by CpG-ODNs by competitive binding to the C-terminal fragment of TLR9. ODN 2088 (0.001, 0.01, 0.1, 1, 10 μM; 24 h) inhibits the TNF-α secretion in a dose-dependent manner in CpG-ODN 1826 (100 nM) stimulated BMDMs and shows weekly inhibits when stimulated by the TLR7-agonist imiquimod. ODN 2088 (10 μM) stimulates B cells to proliferate. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: Human PBMCs Concentration: 0.01, 0.1, 1, 10 μM Incubation Time: 48 h Result: Showed no cytotoxic for for human PBMCs.
Form:Solid
Specifications
Specifications & Purity
≥90%
Biochemical and Physiological Mechanisms
ODN 2088 is a potent TLR3 , TLR7 and TLR9 inhibitor. ODN 2088 shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6.
Storage
Store at -20°C, Desiccated
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
ANTAGONIST
Purity
≥90%
Names and Identifiers
| Molecular Weight | 4878.00 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.